Several assays for KRAS and BRAF mutations have been developed that involve DNA extraction from a single tumor tissue block, followed by a mutation-specific, polymerase chain reaction (PCR)-based assay or the sequencing of the relevant codons. This evidence concerns the gene KRAS and neoplasm.